Can diabetes or the medication Mounjaro (tirzepatide) cause urinary retention?

Can Diabetes or Mounjaro Cause Urinary Retention?

Yes, diabetes itself is a well-established cause of urinary retention through diabetic bladder dysfunction (diabetic cystopathy), while Mounjaro (tirzepatide) does not appear to cause urinary retention based on current evidence, though it has been associated with other urological symptoms in rare cases.

Diabetes and Urinary Retention

Diabetes is strongly associated with bladder dysfunction that can lead to urinary retention. Longstanding diabetes causes paralysis of the detrusor muscle, leading to voiding difficulties including weak stream, post-void residual urine (PVR), and impaired bladder sensation 1.

Prevalence and Risk Factors

The prevalence of bladder dysfunction is substantial:

• 43-87% of type 1 diabetic patients
• 25% of type 2 diabetic patients 1

The correlation between diabetic cystopathy and peripheral neuropathy ranges from 75-100%, indicating this is primarily a neurological complication 1.

Key risk factors include:

• Diabetes duration (longer duration increases risk)
• Presence of peripheral neuropathy
• Presence of diabetic retinopathy 1

Mechanism of Diabetic Bladder Dysfunction

The pathophysiology involves three main mechanisms 1:

• Detrusor smooth muscle alteration - leading to impaired contractility
• Neuronal dysfunction - denervation causing poor bladder control
• Urothelial dysfunction - altered receptor signaling and prostaglandin release

Clinical Presentation

Common symptoms include 1:

• Incomplete bladder emptying
• Weak urinary stream
• Straining to void
• Intermittency
• Post-void dribbling
• Hesitancy in initiating micturition
• Infrequent voiding
• Recurrent urinary tract infections

Important caveat: In men with diabetes, these symptoms may mimic benign prostatic hyperplasia (BPH), but can actually result from bladder dysfunction due to denervation and poor detrusor contractility rather than obstruction 1.

Mounjaro (Tirzepatide) and Urinary Symptoms

Urinary retention is NOT listed as an adverse effect in the FDA label for Mounjaro 2. The extensive clinical trial data from the SURPASS program, which included thousands of patients, did not identify urinary retention as a safety signal.

Documented Urological Effects

However, one case report describes novel urological symptoms with tirzepatide 3:

• A 40-year-old male developed urinary frequency, penile pruritus, dysuria, pelvic/perineal pain, and sexual dysfunction 3-4 weeks after starting tirzepatide
• Symptoms resolved within 10 days of discontinuation
• This represents urinary irritative symptoms, not retention

Known Gastrointestinal Effects

The well-documented adverse effects of Mounjaro are primarily gastrointestinal 2, 4, 5, 6:

• Nausea, vomiting, constipation
• Delayed gastric emptying
• Rare cases of small bowel obstruction

Clinical Approach

When Evaluating Urinary Retention in a Diabetic Patient on Mounjaro:

1. Attribute urinary retention to diabetes first - This is a well-established complication with strong evidence 1

2. Assess diabetes-related risk factors:

   • Duration of diabetes (>20 years significantly increases risk)
   • Presence of peripheral neuropathy (check for sensory deficits, absent reflexes)
   • Presence of retinopathy
   • Other autonomic dysfunction (gastroparesis, erectile dysfunction, orthostatic hypotension)

3. Measure post-void residual volume - Essential for confirming retention 1

4. Rule out other causes:

   • In men: BPH (though symptoms overlap with diabetic bladder)
   • Urinary tract infection (diabetics are at higher risk) 1
   • Other medications with anticholinergic properties 7

5. Consider urodynamic testing if diagnosis unclear or initial management fails 1

Regarding Mounjaro Specifically:

Do not discontinue Mounjaro based on urinary retention alone - there is no established causal relationship. However, if the patient develops:

• Urinary frequency, dysuria, or pelvic pain (irritative symptoms) that temporally correlate with tirzepatide initiation
• Negative infectious workup
• Consider a trial discontinuation to assess symptom resolution 3

Management Priority

Focus management on treating diabetic bladder dysfunction through:

• Timed voiding schedules
• Double voiding techniques
• Intermittent catheterization if significant residual volumes
• Addressing underlying glycemic control
• Urological referral for persistent symptoms

The evidence strongly supports diabetes as the culprit for urinary retention, not Mounjaro 1.